Investigational BLD-2660 for Fibrosis Treatment Enters Phase 1 Trial, Blade Announces
Blade Therapeutics has launched a Phase 1 clinical trial to evaluate BLD-2660, its lead therapy candidate for the treatment of fibrosis, the company recently announced. The randomized, placebo-controlled, dose-escalation Phase 1 trial (NCT03559166) is enrolling an estimated 88 healthy volunteers to assess the safety and pharmacokinetics — how…